Molecular Biometrics has raised $12 million in a Series A round of venture capital from Boston-based Oxford Bioscience Partners and Safeguard Scientifics. The cash will be used to support development of ViaMetrics, a diagnostic tool to help doctors identify which embryos created through in vitro fertilization have the greatest chance to become viable embryos. The company is currently headquartered in Chester, NJ, although it plans to move to the Boston area in early 2009.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
